Rosenblum Silverman Sutton’s AbbVie ABBV Stock Holding History

Rosenblum Silverman Sutton’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$268K	Buy	+4,100	New	+$258K	0.12%	76

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Rosenblum Silverman Sutton's ABBV Position: Q4 2014 in Review

Rosenblum Silverman Sutton opened a new position in AbbVie (ABBV) in Q4 2014: 4,100 shares worth $268K. The stake represents 0.12% of the portfolio and ranks #76 among its holdings.

1,604 funds tracked by Wall St. Rank hold ABBV as of Q4 2014.

Rosenblum Silverman Sutton held 4,100 shares of AbbVie worth $268K as of Q4 2014.
AbbVie was a new Rosenblum Silverman Sutton position in Q4 2014.
AbbVie made up 0.12% of Rosenblum Silverman Sutton's portfolio in Q4 2014, its #76 holding.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q4 2014.

Based on Rosenblum Silverman Sutton's 13F filing for Q4 2014, filed 17 Feb 2015.